The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Dec. 3, 5:40 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #44. Valeant Pharmaceuticals Solta Medical, Inc.

Acquirer: Valeant Pharmaceuticals (VRX)
Acquiree: Solta Medical, Inc. (SLTM)
Details: Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Solta expired at 11:59 p.m., New York City time on January 14, 2014. The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.

Valeant Pharmaceuticals International is a pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). Co. has two operating and reportable segments: Developed Markets, which focuses in dermatology, neurology, gastrointestinal disorders, and eye health therapeutic; and Emerging Markets, which focuses primarily on branded generics, OTC products, and medical devices.

Open the VRX Page at The Online Investor »

Valeant Pharmaceuticals International is a pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). Co. has two operating and reportable segments: Developed Markets, which focuses in dermatology, neurology, gastrointestinal disorders, and eye health therapeutic; and Emerging Markets, which focuses primarily on branded generics, OTC products, and medical devices.

Open the SLTM Page at The Online Investor »

Company Name: 
Valeant Pharmaceuticals International Inc
Stock buyback: 
VRX buyback
Website: 
www.valeant.com
Sector: 
Drugs & Pharmaceuticals
Company Name: 
Solta Medical, Inc
Website: 
www.solta.com
Sector: 
Medical Instruments & Supplies
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 44 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.